Author/Editor     Takač, Iztok
Title     Hormonsko nadomestno zdravljenje
Translated title     Hormone replacement therapy
Type     članek
Source     In: Čokolič M, Hojs R, Glaser M. Zbornik 1. osteološki dnevi; 2007 okt 19-20; Maribor. Maribor: Univerzitetni klinični center,
Publication year     2007
Volume     str. 62-71
Language     slo
Abstract     Majority of middle-aged women in peri- and postmenopause experience menopausalsymptoms, which are a direct consequence of a decrease in estrogen levels and are also the most frequent indication for hormone replacement therapy (HRT). HRT is indicated in urogenital atrophy, for prevention and treatment of osteoporosis and in premature menopause (before age of 40). In HRT the dose of estrogen and gestagen should be lowest needed to relieve symptoms and the duration of treatment is based on the indication. Before HRT pretreatment assesment is neccessary and during treatment patients should ne reevaluated annually. Long-term HRT involves some additional risk of breast cancer, venous and pulmonary thromboembolic disease, gallbladder stones and endometrial cancer. Before starting HRT, the contraindications for this treatment should be evaluated.
Summary     V obdobju peri- in pomenopavze se pri večini žensk zaradi pomanjkanja estrogenov pojavijo menopavzni simptomi, ki so tudi najpogostejša indikacija za hormonsko nadomestno zdravljenje (HNZ). HNZ uvedemo tudi pri urogenitalni atrofiji, za preprečevanje in zdravljenje osteoporoze ter ob nastopu menopavze pred 40. letom. Pri HNZ uporabljamo najnižje možne odmerke estrogenov in gestagenov, trajanje zdravljenja pa zavisi od indikacije. Pred uporabo HNZ je potrebno opraviti določene preiskave, bolnice med zdravljenjem pa redno, enkrat letno, spremljamo. Podaljšano HNZ povečuje tveganje za nastanek raka dojk, venske tromboze in pljučne embolije, žolčnih kamnov ter raka endometrija. Pred uvedbo HNZ moramo upoštevati kontraindikacije za to vrsto zdravljenja.
Descriptors     POSTMENOPAUSE
ESTROGENS